July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Effect of Bevacizumab vs. Ranibizumab for Macular Edema Due to Retinal Vein
Occlusion in Real World Practice, Taiwan Experience
Author Affiliations & Notes
  • Yu Ti Teng
    National Cheng Kung University Hospital , Tainan, Taiwan
  • Po An Lin
    National Cheng Kung University Hospital , Tainan, Taiwan
  • Yi-Sheng Chang
    National Cheng Kung University Hospital , Tainan, Taiwan
  • Chun Chieh Lai
    National Cheng Kung University Hospital , Tainan, Taiwan
  • Min Hsiu Shih
    National Cheng Kung University Hospital , Tainan, Taiwan
  • Shih Hao Wang
    National Cheng Kung University Hospital , Tainan, Taiwan
  • Footnotes
    Commercial Relationships   Yu Ti Teng, None; Po An Lin, None; Yi-Sheng Chang, None; Chun Chieh Lai, None; Min Hsiu Shih, None; Shih Hao Wang, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4272. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yu Ti Teng, Po An Lin, Yi-Sheng Chang, Chun Chieh Lai, Min Hsiu Shih, Shih Hao Wang; Effect of Bevacizumab vs. Ranibizumab for Macular Edema Due to Retinal Vein
      Occlusion in Real World Practice, Taiwan Experience. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4272.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the effect of intravitreal injection of bevacizumab and ranibizumab for macular edema caused by retinal vein occlusion.

Methods : This was a retrospective chart review study. Patients diagnosed as BRVO, CRVO or Hemi-RVO during 2014 to 2016 in National cheng Kung University Hospital were included. Refractory macular edema was defined as persistent or recurrent macular edema after more than 3 times of IVI treatment. Visual acuity and central retinal thickness improvement were collected in 6 months and 12 months follow-up periods to compare the treatment effect of bevacizumab and ranibizumab.

Results : 93 patients were included, while 64 patients received bevacizumab injections and 29 patients ranibizumab injections. Totally, 36 patients (38.7%) received more than 3 times of injections but still had persistent or recurrent macular edema. The refractory macular edema rates were similar between bevacizumab group and ranibizumab group (40.6% vs 34.5%, p value = 0.65). There was no significant difference in visual acuity improvement and central retinal thickness decrease between these two groups in 6 months and 12 months follow-up period. In sub-group analysis, bevacizumab revealed no inferiorities to ranibizumab in visual acuity improvement or central retinal thickness decrease in both BRVO and CRVO groups.

Conclusions : For patients with macular edema caused by retinal vein occlusion, intravitreal bevacizumab was noninferior to ranibizumab in visual acuity and central retinal thickenss improvement after 6 and 12 months after treatment.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

<!--StartFragment-->
Fig. 1. Change of visual acuity at 6 and 12 months in IVB and IVR groups
<!--EndFragment-->

<!--StartFragment-->
Fig. 1. Change of visual acuity at 6 and 12 months in IVB and IVR groups
<!--EndFragment-->

 

Fig. 2. Change of CST at 6 and 12 months in IVB and IVR groups
<!--EndFragment-->

Fig. 2. Change of CST at 6 and 12 months in IVB and IVR groups
<!--EndFragment-->

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×